Navigation Links
FDA accepts Labopharm's response for once-daily tramadol as complete Class 2 response
Date:7/17/2008

- FDA Assigns PDUFA Date of January 2, 2009 -

LAVAL, QC, July 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that the response that it submitted to the U.S. Food and Drug Administration (FDA) on July 2, 2008, including the additional analysis of existing data as suggested by the Agency, has been accepted as a complete, Class 2 response. The action date assigned by the FDA under the Prescription Drug User Fee Act (PDUFA) is January 2, 2009.

About Labopharm's Once-Daily Tramadol Product

Labopharm's once-daily tramadol product is based on the Company's proprietary Contramid(R) technology, which provides a dual matrix delivery system allowing both rapid and sustained drug release that maintains blood levels within the therapeutic range providing a full 24 hours of pain relief. The Company believes that maintaining drug concentrations within the therapeutic range has the advantage of fewer and less severe side effects while maintaining efficacy. Under its global commercialization program, Labopharm's once-daily tramadol product has been launched in 12 countries, including the five largest markets in Europe and Canada and is approved in 18 other countries. Including those countries in which its product has been launched, Labopharm has licensing and distribution agreements in place for more than 50 markets globally.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
2. Partnering With MyPyramid: NUTRIKIDS Accepts the Challenge to Help Families Step Up to Healthier Living
3. AMEX Accepts Lorus Plan to Meet AMEXs Continued Listing Standards
4. Mike Huckabee Accepts Values Voter Presidential Debate
5. ev3 Inc. Accepts Resignation of Dr. John Simpson
6. Lieutenant Governor Catherine Baker Knoll Accepts Women in Government Presidential Leadership Award
7. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
8. Governor Rendell Accepts National Health Care Reform Pioneer Award
9. American Stock Exchange Accepts Encisions Plan to Regain Compliance
10. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
11. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 31, 2014 Springboard ... for its small scale BioPro™ biodiesel processors, announced ... will further improve the performance and efficiency of ... GL95/MC12/BD380 trio will recover more than ... in with the glycerin by-product produced while making ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 The Memory Healer ... created by Alexander Lynch, whose father suffered from Alzheimer's disease. ... dramatic moment, caused by his father's disease. His father pointed ... was the crucial moment when the author of this method ... dad. , The Memory Healer program is based on ...
(Date:10/31/2014)... Missouri (PRWEB) October 31, 2014 At ... country about families narrowly escaping carbon monoxide poisoning in ... looms just weeks away, one family-owned, Missouri-based heating and ... approach to making sure families start the home heating ... safe and secure. , Beginning Nov. 1, 2014, ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... – New research suggests that insomnia is a major ... other unintentional fatal injuries. The results underscore the importance ... National Healthy Sleep Awareness Project. , Results show that ... dose-dependent manner with the number of insomnia symptoms present. ... times more likely to die from a fatal injury ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... March 17 eCardio Diagnostics ( www.ecardio.com ) ... Academic Medicine initiative to provide a tailored offering ... first time an arrhythmia monitoring company has addressed ... academic medical centers. "At eCardio, we work ...
... Pa., March 16 BioTrends Research Group, Inc. has ... through its TreatmentTrends(TM) series which ... survey data collected from Dermatologists and Rheumatologists. The ... of ChartTrends(TM) reports which aim ...
... NATIONALLY BROADCAST ,LIFE PERSPECTIVES, RADIO PROGRAMFRIENDSWOOD, Texas, March 16 ... a developer, manager and owner of faith-based senior living ... a new ticker symbol and will begin trading on ... 17, 2009. The Company also announced that its Chairman ...
... /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... Company is calling its $12.4 million of 10.0% Secured,Promissory ... In addition, the,Company announced the completion of the following ... million in principal amount 10.0% senior secured, ...
... Message Spread on Web Sites, YouTubeDon,t Move From ... Human Services to Danger in Rescinding Conscience ProtectionsWASHINGTON, ... Catholics in the United States to tell the ... regulations governing conscience protections for health care workers.This ...
... for Operating Activities Declines to Less Than $1 ... Additional Cost Savings During 2009 & 2010First Quarter ... STAAR Surgical Company (Nasdaq: STAA ... minimally invasive ophthalmic products, today reported financial results ...
Cached Medicine News:Health News:eCardio Diagnostics Launches Academic Medicine Initiative 2Health News:BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis 2Health News:TrinityCare Senior Living Trading Under New Symbol 'TCSR' 2Health News:BMP Sunstone Exchanges and Calls Outstanding Notes Due May 2009 2Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 2Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 3Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 2Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 3Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 4Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 5Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 6Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 7Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 8Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 9Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 10Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 11Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 12Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 13Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 14Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 15Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 16Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 17Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 18Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 19Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 20Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 21Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 22Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 23Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 24Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 25
(Date:10/31/2014)... , October 31, 2014 Multigate ... Australian patents of B. Braun Melsungen AG (B. Braun) by ... safety IV catheters manufactured by Poly Medicure Ltd (Polymed). ... Australia proceeding number VID 463 of 2013 can ... the detailed judgment, Multigate was found to have infringed claim ...
(Date:10/31/2014)... Electronic prescribing or E-Prescribing system ... related information between prescriber, dispenser and pharmacy ... and nurse practitioner to transmit a new ... during pharmacy operations. E-Prescribing system has a ... medical lists, conducts all security checks and ...
(Date:10/30/2014)... Oct. 30, 2014 /CNW/ - Atlantic Canadians will save ... between Canada,s provinces and territories ... President of the Canadian Generic Pharmaceutical Association (CGPA), said ... while speaking at the Atlantic Summit on Healthcare and ... which is being hosted by the Public Policy Forum ...
Breaking Medicine Technology:B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2E-Prescribing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3
... WELLESLEY HILLS, Mass., Feb. 19 Joseph F. ... Creditors of ActivBiotics, announced,today the design of a ... adequately by currently approved antibiotics. Rifalazil, the,most potent ... may,provide a better treatment option for Chlamydia STD. ...
... Show Cethromycin Not Associated with QT Prolongation- ... Cardiac Safety Profile Strengthens NDA-, CHICAGO, Feb. 19 ... today announced positive results from Trial,CL07-001, a thorough QT ... study was conducted to evaluate the cardiac,safety of cethromycin ...
Cached Medicine Technology:ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD 2Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 2Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 3Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 4Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 5Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 6
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
Medicine Products: